Guerbet S A : 09/24/2020 - Half-year Sales & Results (presentation)

HY 2020 - HALF-YEAR SALES & RESULTS

SEPTEMBER 24, 2020

Disclaimer

Certain information included in this presentation and other statements or materials published by Guerbet (the "Company") are not historical facts but are forward-looking statements. These forward-looking statements refer in particular to the Company's management's business strategies, its expansion and growth of operations, future

events, trends or objectives and expectations, which are naturally subject to risks and contingencies that may lead to actual results materially differing from those

explicitly or implicitly included in these statements.

Forward-looking statements speak only as of the date of this presentation and, subject to any legal requirement, the Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future events or for any other reason and any opinion expressed in this presentation is subject to change without notice. Such forward looking statements are for illustrative purposes only. Forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company. These risks and uncertainties include among other things, the uncertainties inherent in research and development of new products, including future clinical trial results and analysis of clinical data (including post-marketing data), decisions by regulatory authorities, such as the Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as

their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. A detailed description of risks

and uncertainties related to the Company's activities is included under Chapter 4.3 "Risk factors" in the Registration Document (Document de Référence) of the Company which has been filed with the French Financial Markets Authority on April 5, 2017 under the number n°D-17-0323 and is available on the Company's website (www.guerbet.com).

This presentation contains statistics, data and other information relating to markets, market sizes, market shares, market growth, market positions and other industry data pertaining to the Company's business and markets. Such information is based on the Company's analysis of multiple internal and third party sources, including information extracted from market research, governmental and other publicly available information, independent industry publications and information and reports. The Company, its affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry forecasts. Such data and forecasts are included in this presentation for information purposes only.

Some of the financial information contained in this presentation is not directly extracted from the Company's accounting systems or records and does not constitute International Financial Reporting Standards (IFRS) accounting measures, including in particular EBITDA. The Company calculates EBITDA as operating income, with the net allowance for amortization, depreciation and provisions added back in. EBITDA is not a measure of financial performance under IFRS and the definition of the term used by the Company may not be comparable to similar terms used by other companies. Such information has not been independently reviewed or verified by the Company's auditors.

This presentation does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in securities in France, the United States or any other jurisdiction.

2	HY 2020 - HALF-YEAR SALES & RESULTS

Welcome

€817 m in 2019

DAVID HALE

Chief Executive Officer

2 820 employees in 2019

€73m dedicated to R&D ; 9% of sales

JÉRÔME ESTAMPES

Chief Financial Officer

Distributed in over 80 countries

3	HY 2020 - HALF-YEAR SALES & RESULTS

Agility & Resilience despite COVID-19 impact

SALES: IMPACT OF COVID

First-half sales down 9.2% (at current rate)

COVID impact varies by regions

MARGIN: COST CONTROL

Strong cost management

Ahead of cost-to-win targets

CASH / INVENTORY / NET DEBT VIGILANCE

Active cash management

Improvement of WCR - acceleration of deleveraging

MAINTAIN STRATEGIC ROADMAP

Development projects running on a normal basis scenario

4 HY 2020 - HALF-YEAR SALES & RESULTS

GUERBET IS READY FOR

ACTIVITY REIGNITION WITH

AN OPTIMIZED COST

STRUCTURE FAVOURING OPERATIONAL MARGIN

	DIAGNOSTIC IMAGING (DI)			INTERVENTIONAL IMAGING (II)
	€312.5 m ; -11.9% at CER			€35.6m ; +1.9% at CER

Optiray®	Illumena Neo®
		Dotarem®	OptiStar Elite®
Xenetix® Consumables OptiVantage®	Artirem®	Lipiodol® Ultra-Fluid			Microcatheters
		SeQure® and DraKonTM

Patent Blue V

Vectorio®

Excluding Revenue from third party : €348.1m at CER ; (10.6%)

5	HY 2020 - HALF-YEAR SALES & RESULTS

Summary

1. Key highlights
2. Financial results
3. Wrap-up
4. Appendix

Rapid and effective measures to face COVID19 pandemic

PRIORITY : HEALTH & SAFETY

OF OUR EMPLOYEES

Immediate activation of a crisis unit

Commercial & Support working remotely - Industrial / supply chain & technical services teams mobilized on the frontline

• 50 confirmed COVID cases - limited impact on workforce

BUSINESS

CONTINUITY

Business continuity on all Group's industrial sites despite travel restrictions and distancing obligations

Uninterrupted shipping & deliveries to all of our customers

FINANCIAL

PROTECTION

Cost-to-win program continued

Additional savings (Travel/ & fleet expenses, events & promotional material costs, Reduction in training costs) achieved through new ways of working

Solid financial structure -

Continued deleveraging

No PGE (Government loans)

HEALTH OF OUR TEAMS PRESERVED		ASSURED DELIVERY TO OUR CUSTOMERS		SOUND OPERATIONAL COST STRUCTURE

7	HY 2020 - HALF-YEAR SALES & RESULTS

Five teams are working on transversal programs leveraging learnings from

COVID

IMPROVING RESILIENCE	CATCHING MARKET EVOLUTIONS /
OF OUR END-TO-ENDSUPPLY-CHAIN	ADAPTING OUR COMMERCIAL APPROACH

NEXT

UNDERSTANDING NEW GXP'S REGULATION	NORMAL	ENGAGING OUR PEOPLE /
AND COMPLIANCE TRENDS	LIVING OUR MISSION

LEVERAGING DIGITAL SOLUTIONS	ADAPTING OUR ORGANIZATIONS /
	WAYS OF WORKING

8	HY 2020 - HALF-YEAR SALES & RESULTS

Strong impact on activity in Q2 - Activity picking up in Q3

H1 Sales split by month

2020 vs 2019 (€m at current rate)

76.2

68.5		68.9	70.3	69.2	64.8
61.3	59.8	61.8		63.8

51.4	48.2

2019 2020

January	February	March	April	May	June
-11%	+3%	+11%	-27%	-30%	+2%

In line with the market volume evolution

Flat / single digit growth on Q1

Q2 double digit

negative growth market

July: positive / August: sluggish

9 HY 2020 - HALF-YEAR SALES & RESULTS

Strong growth in Asia offset by mitigated trends in Americas and Europe

Split sales & evolution by zone

(in% at CER)

		H1 2020
	+9%
	83.0	-16.6%
H1 2019		-
	157.9
	EMEA
76.2	Americas
189.3	APAC
124.1	107.2
-13.6%

Excluding « Revenue from third party »

10 HY 2020 - HALF-YEAR SALES & RESULTS

Europe & Middle-East: lenghty and widespread confinement

Impact on major Guerbet strongholds (France , Germany, UK, Italy)

Volume & Price impact (MRI)

Gradual return of follow-up exams

Americas: global trade prudence with decline starting mid Q2

Volume low due to erratic stops & go throughout all US & Brazil

Adjusting price (MRI) to preserve Dotarem® footprint

Gradual recovery on Q3

APAC: good performance overall in resilient markets on H1

H1 sales particularly strong

Strong lockdown in Japan but performance preserved thanks to Guerbet's Go-direct move

CT Cath Lab: maintaining market share in all markets

57% of H1	Results in line with market evolution
2020 sales*	Contrast media market volume evolution : -12.8%
	Volume effects mainly due to COVID
-7.9%	First pull through injector sales by Contrast&Care® offer
	COGS reduction & portfolio pruning continues
217.0	199.9
H1 2019	H1 2020

All numbers at CER		Sources: ecmig-gcmig-cmig, ims, encize August 2020 (incl. all products from GE,
*Excluding Other		BAYER, BRACCO & GUERBET excl. Generics from other suppliers)

11	HY 2020 - HALF-YEAR SALES & RESULTS

MRI impacted by regulatory price decreases and COVID

	32% of
	H1 2020
	sales*
			Dotarem® sales
			Contrast media market volume evolution : -16.5%
			Volume market share decline limited to 0.5 point
-18.7%
		Price pressure of generics assumed to increase in 2020

136.4	110.9
H1 2019	H1 2020

All numbers at CER		Sources: ecmig-gcmig-cmig, ims, encize August 2020 (incl. all products from GE,
*Excluding Other		BAYER, BRACCO & GUERBET excl. Generics from other suppliers)

12	HY 2020 - HALF-YEAR SALES & RESULTS

Interventional Imaging continues growth despite COVID

	Robust performance
10% of H1	Continuing to grow through geographical, pricing & indication expansion
2020 sales*	Patent blue V remains a solid performer

		HSG in women undergoing infertility work-up registration in Czech Republic,
		Ireland, Hungary, Netherlands and Denmark
		Lipiodol® Ultra Fluid is currently approved for HSG in 12 countries (USA incl.
		Puerto Rico, Canada)
	+1.9%	Growth relays
		SeQure® & DraKon™ > High Q1 - Limited customer acquisition on Q2,
		reorders on Q2 coming from customers acquired on Q1
34.9		35.6
		R&D programs on track for range extensions for 2021
H1 2019		H1 2020

All numbers at CER

*Excluding Other

13	HY 2020 - HALF-YEAR SALES & RESULTS

MRI: Gadopiclenol - COVID impact limited to 3 months in clinical trials and industrial production

PHASE III - GADOPICLENOL

Test effectiveness and tolerance vs. relevant comparator on a large sample of patients

Patients recruitment & industrialization activities slightly delayed because of Covid- 19 impact on hospitals & installation of equipment

Patient recruitment completed for one of the 2 pivotal phase 3 studies, close to completion for the 2nd pivotal study

Results of clinical studies Q1 2021 - Launch on track for 2023

Phase III full costs of €20 m: 10% on 2018 - 35% in 2019 - 40% in 2020 & 15% in 2021

14	HY 2020 - HALF-YEAR SALES & RESULTS

Digital solutions

Monitors patient radiation exposure

Collects data from all ionizing equipment

Tracks patient exposure history Statistical analysis of dose data

Key feature			Patient		Traceability		Save admin. Time		Key feature
Compatible			Information				Barcode /			Compatible
with all			Injection		Batch Recalls		RFID			with all
imaging			History			Injection			Guerbet
modalities						Adverse				injectors
		Red-Flag			Analytics
				Events
			Patients

Sales in Europe

Contract in place for US

Next in line : commercial launch in APAC

Room for growth till the end of the year

15 HY 2020 - HALF-YEAR SALES & RESULTS

2020 : Confirmation of the quality - 1st sales in US

1st feedbacks are very positive

Implemented protocol library to increase productivity through the new feature « One click protocol »

Interoperability and data management with InterSystems Solutions systematically integrated into any commercial offer

Digital Solutions a key part of creating customer value and differentiating our Guerbet Solutions

Market Dynamics in Diagnostic Imaging

Digital solutions like Contrast & Care with a SaaS revenue model bring

value to customers and make our solutions sticky

• Steady but slow volume growth
• Increasing power of purchaser vs radiologist
• Generics abundant
• Individual products viewed

as commodities

• Rising Price Pressure
• Need to find ways to differentiate offerings
• Positioning solutions ("UNIK offer" ) vs. Individual products

• Contrast media usage
  → auto-replenishment & inventory management
• Protocols used → protocol standardization
• Injector installed → pro-active service, uptime tracking, maintenance planning

Continuous

value

creation

cycle

• Productivity → Automate + digitize administrative tasks
• Traceability + compliance → Less manual entry errors & paper records become digital
• Differentiated Offer → Works on all our injectors

16 HY 2020 - HALF-YEAR SALES & RESULTS

• Automatically extracts needed patient data in advance of exam
• Electronically captures all injection data
• Digitally puts information back into patient record for radiologist

2 distribution partnerships accelerating transformation of Guerbet's commercial network in AI

Patient Synopsis - 1st distribution partnership

AI solution that extracts relevant patient information (from medical files mostly unstructured) and summarizes it into concise dashboard at time of read

Distribution partnership for the USA

Icobrain a fully automated solution

Designed for radiologists and clinicians,

To help quantify brain volume and brain volume changes on MRI and CT scans,

To help interpret and communicate the patient's

condition,

For patients with neurological diseases

Ready for
commercial
acceleration
		GUERBET AI SOLUTION
		IN PROSTATE & LIVER
		CANCER WILL BENEFIT
		FROM THE
		INFRASTRUCTURE PUT IN
First sales in		PLACE FOR PATIENT
	SYNOPSIS & ICOBRAIN
progress and
funnel growing

17 HY 2020 - HALF-YEAR SALES & RESULTS

Summary

1. Key highlights
2. Financial results
3. Wrap-up
4. Appendix

Half year revenue down vs prior year, affected by the COVID19 crisis

Sales evolution at constant &
current exchange rates (in €m)
	-8.4%	-9.2%	H1 2020 Performance
400.6	367.1		Impact for COVID 19
		starting in March
	363.7
			Impact of health crisis in
			Europe and the Americas,
			while good sales in Asia
			In June sales rebound to
			positive performance with
			+1,6% (At current rate)
			Performance without third
			party -10.6%
			€3.4 m FOREX impacts
			mainly driven by Brazilian
2019	2020		Real
At CER	At Current FX

19	HY 2020 - HALF-YEAR SALES & RESULTS

EBITDA

	H1 2019		H1 2020
IFRS €m	As published	% revenue	As published	% revenue
	Incl. IFRS 16(1)		Incl. IFRS 16(1)
Net sales	400.6	100.0%	363.7	100.0%
Other revenue	2.1	0.5%	5.3	1.5%
Supplies used in operations	(79.4)	(19.8)%	(85.7)	(23.6)%
Staff costs	(123.1)	(30.7)%	(123.9)	(34.1)%
External expenses	(129.8)	(32.4)%	(100.3)	(27.6)%
Taxes other than on income	(10.3)	(2.6)%	(9.9)	(2.7)%
Other operating income and expenses	1.5	0.4%	4.0	1.1%
EBITDA	61.6	15.4%	53.3	14.7%

1. : the amounts of leases qualifying for IFRS16 are excluded from EBITDA (positive impact on EBITDA) and reclassified in depreciation and amortization and financial costs

20 HY 2020 - HALF-YEAR SALES & RESULTS

EBITDA Evolution

EBITDA Evolution in €m

	-2.8		+3,9
		+19.9
			-2.0
		-9.7
61.6		-17.7	53.3

EBITDA H1 2019	FX	Price	Volume / Mix	Fixed Cost	R&D phasing Other / One EBITDA H1 2020
				reduction	offs

21	HY 2020 - HALF-YEAR SALES & RESULTS

Operating Income

	H1 2019		%	H1 2020		%
IFRS €m	As published	As published
revenue	revenue
	Incl. IFRS 16	(1)	Incl. IFRS 16	(1)
EBITDA	61.6		15.4%	53.3		14.7%
Allowances for depreciation	(29.6)		(7.4)%	(30.7)		(8.4)%
Provisions	(9.8)		(2.4)%	2.8		0.8%
Operating Income	22.3		5.6%	25.4		7.0%

1. : the amounts of leases qualifying for IFRS16 are excluded from EBITDA (positive impact on EBITDA) and reclassified in depreciation and amortization and financial costs

22 HY 2020 - HALF-YEAR SALES & RESULTS

Net Income

	H1 2019		H1 2020
IFRS €m	As published	% revenue	As published	% revenue
	Incl. IFRS 16 (1)		Incl. IFRS 16 (1)
Operating Income	22.3	5.6%	25.4	7.0%
Net interest expense	(5.4)	(1.4)%	(4.4)	(1.2)%
Net currency gains/losses &	7.9	2.0%	(10.0)	(2.7)%
other financial income/loss
Income tax	(5.7)	(1.4)%	(2.8)	(0.8)%
Net Income	19.0	4.8%	8.2	2.3%

1. : the amounts of leases qualifying for IFRS16 are excluded from EBITDA (positive impact on EBITDA) and reclassified in depreciation and amortization and financial costs

*: Incl. other financial income & expenses

23 HY 2020 - HALF-YEAR SALES & RESULTS

Balance sheet

	June 30 2019	June 30 2020	December 31 2019
ASSETS	As published incl.	As published incl.	As published incl.
	IFRS 16	IFRS 16	IFRS 16

Non-current assets	494.8	483.8	493.6
of which fixed assets	454.8	452.6	462.5
Inventories	287.1	221.0	236.6
Trade receivables	144.7	118.5	140.3
Other current assets	141.8	128.6	138.3
of which CCE	75.9	77.5	81.4
Assets held for sales	0.0	12.9	0.0
(Canada)
Total Balance sheet	1 068.4	964.8	1 008.9

	June 30 2019	June 30 2020	December 31 2019
EQUITY & LIABILITIES	As published incl.	As published incl.	As published incl.
	IFRS 16	IFRS 16	IFRS 16

Shareholders' equity	367.9	374.9	389.2
Non-current liabilities	412.0	372.7	403.7
of which financial debt	340.2	314.9	340.7
Trade payables	69.1	67.2	67.8

Other current liabilities	219.4	146.1	148.2
of which financial debt	93.7	31.9	37.3
Related labilities to	0.0	3.9	0.0
assets held for sales
(Canada)
Total Balance sheet	1 068.4	964.8	1 008.9

24 HY 2020 - HALF-YEAR SALES & RESULTS

Free cash-flow

		H1 2019	H1 2020
	IFRS €m	As published	As published
		(incl. IFRS 16)	(incl. IFRS 16)
	Cash flow from operations	62.3	45.9
	Change in WCR	(32.9)	12.4
	Net capital expenditure	(33.6)	(27.8)
	Dividends	(10.7)	0.0
	Capital increase	0.0	0.1
	Interests paid	(3.5)	(1.8)
	Income tax paid	(7.9)	1.7
	Exchange	(6.8)	(2.9)
	Other Inflows (outflows) of cash	0.0	(0.3)
	Free Cash Flow	(33.0)	27.2

25 HY 2020 - HALF-YEAR SALES & RESULTS

Deleveraging on a normal basis

		Net debt					Net debt / EBITDA*				Net debt / Shareholder equity
358.1				3.06
							0.97
		269.3	255.4					2.74
					2.61
										0.72	0.7

H1 2019 as	H1 2020 as	H1 2020	H1 2019 as	H1 2020 as	H1 2020	H1 2019 as	H1 2020 as	H1 2020 restated
published (Incl.	published incl.	restated excl.	published (Incl.	published incl.	restated excl.	published (Incl.	published incl.	excl. IFRS 16
IFRS 16)	IFRS 16	IFRS 16	IFRS 16)	IFRS 16	IFRS 16	IFRS 16)	IFRS 16

*: EBITDA of the last rolling 12 months

26	HY 2020 - HALF-YEAR SALES & RESULTS

Summary

1. Key highlights
2. Financial results
3. Wrap-up
4. Appendix

We have 3 businesses to build on and construct our success for the future - need leadership and governance organized accordingly - starts at the top

	• Products → solutions	• Open new markets	• Grow our IT skill sets… Sales,
What	• Launch Gadopiclenol
• Expand Indications	Marketing, Development
we will	• Lean the portfolio
• Inorganic bolt-ons	• Drive service operational
do	• Actively manage costs
• Dedicated Sales	& commercial excellence
	• Adapt our Go-to-Market
	Generate Cash	Drive Growth	Build a Business

All 3 are needed to be successful

28	HY 2020 - HALF-YEAR SALES & RESULTS

Strong leadership team, with greater diversity and internal mobility,

to accelerate Guerbet's transformation and achieve our strategic priorities

Chief Commercial Officer

Asia Pacific

Mathieu ELIE

Chief Commercial officer North America, Latin America, NEMEA, Southern Europe

Gitte HESSELHOLT

SVP Diagnostic Imaging

Valérie BRISSART

SVP Interventional Imaging

Jean-Francois BLANC

CEO

David HALE

SVP

Technical Operations

(recruitment underway - Jean- Michel Martinet acting in this role)

SVP Development, Medical

• Regulatory Affairs
  Philippe BOURRINET

SVP Research & Innovation, BD&L

Claire COROT

SVP R&D Injection systems, Chief Digital Officer

Francois NICOLAS

New roles

CFO

Jerome ESTAMPES

SVP HR & HSE

Petra ZALABAK

Chief Pharmaceutical Officer,

Pierre ANDRÉ

29 HY 2020 - HALF-YEAR SALES & RESULTS

A differentiated strategy by zones to capture growth opportunities

NAM, EMEA, LATAM	APAC Main Challenge & Opportunity:
Low single digit growth -
Double digit growth - Geographic expansion
Defend core business and boost new segments of II & Digital

	Main Challenges & Opportunities		Main Challenges & Opportunities
• Defend Dotarem & Successfully launch	•	Expansion in China & India
	Gadopiclenol	•	Continue Go Direct Japan
•	Maintain XRay Momentum	•	Launch Gadopiclenol
• Expand Injector & Consumables	•	Launch II Medical Devices
• Boost on II MedicalDevices & Digital
•	Commercial Transformation

30	HY 2020 - HALF-YEAR SALES & RESULTS

Optimization of the Group's industrial plan

SALE OF PHARMACEUTICAL SITE IN MONTREAL

Characteristics

240 employees

Filling & finishing for Optiray®

Manufacture non strategical products

€16.6 m of sales in H1 2020 with very low margin

Anticipated benefits of the transaction

Maximization of utilization of the production capacities of the other sites

Easier inventory management in connection with the improvement of WCR

€10m of savings per year starting in 2022

Industrial relevant facts

Good resilience demonstrated during the COVID-19 crisis in all regions (Europe, NORAM, LATAM and APAC) for our suppliers

Progress on Gadopiclenol with the launch of the first industrial batches

Return to performance in Dublin: capacity increase underway

Rationalization of the supply chain in Europe

31 HY 2020 - HALF-YEAR SALES & RESULTS

Active targets screening

		MEDICAL		EXPAND
FIELDS OF INTEREST		SOFTWARE
	DISPOSABLES	PORTFOLIO

COMMERCIAL	DIRECT	DISTRIBUTION	TECHNOLOGY	WHITE
ACQUISITION	DEAL	ACQUISITION	LABEL
ORGANIZATION

HOW WE DO IT ?

32	HY 2020 - HALF-YEAR SALES & RESULTS

Guerbet's CSR policy is structured around 4 pillars with key objectives and actions

Our CSR policy is structured around 4 pillars

Imaging products and services designed to improve patient prognosis and quality of life

A responsible social policy developed around five main themes: diversity, prevention, recognition, commitment and accountability

An HSE policy that gives absolute priority to safety of people while also minimizing environmental impacts at all levels

Business ethics to promote the fight against corruption, prevention of conflicts of interest and anti-competitive practices as well as respect for the medical code of ethics

Guerbet has substantially improved its position in the field of business ethics and CSR policy, receiving support at the highest level

Actions taken by Guerbet to improve its responsible purchasing policy are also recognized in the ratings

With respect to labor policy, the indicators for work conditions, health & safety and skills development have significantly increased

33 HY 2020 - HALF-YEAR SALES & RESULTS

20202020

ACHIEVEMENTSTARGETS

0.6 0.9

ACCIDENTS AT WORK

Total workforce

186 207

WATER CONSUMPTION 1L / 1kg or 1L product

manufactured

37 47

ENERGY CONSUMPTION

kWh / 1kg or 1L of

Product manufactured

Guidance 2020

Given the impact of generics, and in the context of a stabilized

health crisis with normal functioning of the hospital system

SALES: H2 SIMILAR TO H1

EBITDA AROUND 14% OF REVENUES

CONTINUED DELEVERAGING &

CASH GENERATION

34 HY 2020 - HALF-YEAR SALES & RESULTS

Financial communication calendar

3rd quarter 2020 revenue: October 22, 2020 after trading

Sales 2020: February 11, 2021 after trading

2020 Full-year results: March 24, 2021 after trading

35 HY 2020 - HALF-YEAR SALES & RESULTS

QUESTIONS & ANSWERS

Summary

1. Key highlights
2. Financial results
3. Outlook
4. Appendix

R&D Portfolio

EARLY DEVELOPMENT

LATE DEVELOPMENT

REGISTRATION		RECENTLY LAUNCHED
	(< 2 YEARS)

A DIAGNOSTIC

IMAGING

CONTRAST MEDIA

INJECTION SYSTEMS

DIGITAL SOLUTIONS

-

Confidential

Liver Advisor, future releases

Prostate Advisor V1

Artificial Intelligence

(IBM Watson for Imaging

partnership)

Microsphere

Embolization

Gadopiclenol

Upgrades Optistar Elite®

Liver Advisor V1

Artificial Intelligence

(IBM Watson for Imaging

partnership)

Contrast & Care® cloud

Patent Blue V

new registrations

-

OptiVantage® Multi-use

ASEAN

Illumena® Neo

Asia

-

SeQure® and DraKon™

Asia wave 2, LATAM wave 2

-

OptiVantage® Multi-use

Europe

OptiOne® CT

Asia

Dose&care®

Contrast&care®

Patient Synopsis®

Icobrain®

SeQure® and DraKon™

USA, Europe

Asia wave 1, LATAM wave 1

1. INTERVENTIONAL IMAGING

Confidential

38 HY 2020 - HALF-YEAR SALES & RESULTS

New microcatheters

Accurate

Lipiodol®

New indications

Vectorio®

Asia wave 2

Lipiodol®

EMEA wave 2, Asia, LATAM

Vectorio®

EMEA wave 2, LATAM,

Asia Wave 1

Performance of the Guerbet share

At September 18th, 2020

Price	€ 28
Capitalization	€ 353 m
High since January, 2020	€ 43.8
Low since January, 2020	€ 26.6
Perf. since January, 2020	- 34.3 %

Indexes

CAC Mid &Small, CAC All-Shares

Securities trading info

Code ISIN	FR0000032526
Symbol	GBT
Reuters Code	GRBT.PA
Bloomberg Code	GBT:FP
Number of shares	12 600 874
Market segment	Euronext B

Historical performance since January 2020

39 HY 2020 - HALF-YEAR SALES & RESULTS